The Value of 68Ga-grazytracer PET in Monitoring Responses to Immunotherapy of Gastrointestinal Malignancies
NCT06644274 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 40
Last updated 2024-12-11
Summary
This study aims to investigate the value of 68Ga-grazytracer in predicting the efficacy of immunotherapy for gastrointestinal malignancies.
Conditions
Sponsors & Collaborators
-
Ruijin Hospital
lead OTHER
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-10-20
- Primary Completion
- 2026-06-30
- Completion
- 2027-07-31
Countries
- China
Study Locations
More Related Trials
-
A Study to Evaluate the Diagnostic Efficacy of 68Ga- MY6349 PET/CT in Patients With Tumours
NCT06770478 ·Status: RECRUITING ·Phase: NA
-
68Ga-grazytracer PET/CT of Tumor Responses to Immunotherapy
NCT05000372 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Target-specific immunoPET Imaging of Digestive System Carcinoma
NCT06715839 ·Status: RECRUITING ·Phase: NA
-
68Ga-NYM096 PET/CT in Various Kinds of Cancer
NCT07144748 ·Status: RECRUITING ·Phase: NA
-
The Role of 18F-FDG&68Ga-FAPI PET/CT in the Assessment of Conversion Therapy Efficacy in Gastric Cancer with Peritoneal Metastasis.
NCT06597526 ·Status: RECRUITING
-
Comparative Study of 99mTc-FAPI SPECT/CT and 68Ga-FAPI PET/CT
NCT05444686 ·Status: UNKNOWN ·Phase: NA
-
68Ga-ICAM-1pep PET/CT in Cancer Patients
NCT04596670 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
68Ga-PSMA-11 PET/CT in Patients With Various Types of Cancer
NCT04831541 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Application of 68GA-labeled CD73 Targeting Probe PET/CT Imaging in the Diagnosis of Malignant Tumor
NCT06844110 ·Status: RECRUITING ·Phase: NA
-
Study of 64Cu-FAPI-XT117 PET/CT in Patients With Malignant Solid Tumors
NCT05930457 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluating the Potential Usefulness of 18F-AlF-FAPI PET/CT in Patients With Gastrointestinal Tumors and Compared With 18F-FDG PET/CT
NCT05430841 ·Status: COMPLETED ·Phase: NA
-
Clinical Evaluation of [68Ga]Ga-XT771 PET for Diagnosis in Patients With Glioblastoma and Clear Cell Renal Cell Carcinoma
NCT07067905 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
The Value of PET Imaging Targeting Granzyme B in Predicting Efficacy and Prognosis in T-NK Cell Lymphoma
NCT06863441 ·Status: NOT_YET_RECRUITING
-
A Study of [68Ga]Ga-NOTA-RG2 PET Imaging in the Diagnosis of Hepatocellular Carcinoma
NCT06148155 ·Status: RECRUITING ·Phase: NA
-
CLDN18.2 Targeting PET Imaging in Patients With Gastrointestinal Tumors
NCT04883970 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
68Ga-TCR-FAPI PET/CT in Patients With Various Types of Cancer
NCT06084767 ·Status: RECRUITING ·Phase: NA
-
68Ga-NY104 PET/CT in Patients With Metastatic Clear Cell Renal Cell Carcinoma
NCT05879471 ·Status: UNKNOWN ·Phase: PHASE2
-
68Ga-PMD22 PET/CT Examination Targeting CLDN18.2
NCT05937919 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Diagnosis of Metastatic Tumors on 68Ga-FAPI-RGD PET-CT and Radioligand Therapy With 177Lu-FAPI-RGD
NCT06638034 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
68Ga-NOTA-NFB: Radiation Dosimetry in Healthy Volunteers and Applications in Glioma Patients or Breast Cancer Patients
NCT02327442 ·Status: UNKNOWN
-
64Cu/68Ga Labelled EB-ss-CPT PET/CT Scan in Colorectal Cancer
NCT05891028 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Energy CT in Imaging and Diagnosis of Gastric Cancer
NCT06869694 ·Status: RECRUITING
-
Dual SSTR2 and Integrin αvβ3 Targeting PET/CT Imaging
NCT02817945 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
PD-L1 Targeting Molecular Imaging of Solid Tumors
NCT04629326 ·Status: RECRUITING ·Phase: NA
-
Comparing 68Ga-CTR-FAPI and 18F-FDG PET/ CT in Cancer Detection
NCT06945432 ·Status: COMPLETED